A non-ST elevation myocardial infarction, commonly called NSTEMI, is a type of heart attack where blood flow to part of the heart muscle is severely reduced but not completely blocked. It accounts for a large share of all heart attacks and, while generally less immediately dangerous than its counterpart (STEMI), it still causes lasting heart damage and carries serious long-term risks.
How NSTEMI Differs From a STEMI
All heart attacks involve interrupted blood supply to the heart muscle, but the two main types differ in how completely that supply is cut off. In a STEMI (ST-elevation myocardial infarction), a blood clot completely blocks a coronary artery, starving a large section of heart tissue. In an NSTEMI, the blockage is typically partial. A non-occlusive blood clot, usually forming on a ruptured fatty plaque inside an artery wall, narrows the vessel enough to damage heart muscle without sealing it off entirely.
That said, the distinction isn’t always clean. Some NSTEMI patients do turn out to have a fully blocked artery that simply doesn’t produce the classic electrical pattern on a heart tracing. This is one reason NSTEMI patients are a more varied group, and why doctors sometimes need further testing before deciding on the best treatment approach.
The names themselves come from what shows up on an electrocardiogram (ECG). A STEMI produces a characteristic rise in a specific part of the heart’s electrical signal called the ST segment. An NSTEMI does not show that rise. Instead, it may show ST-segment depression, new changes in the T-wave pattern, or sometimes only subtle abnormalities that require careful interpretation.
Symptoms to Recognize
NSTEMI symptoms often overlap with those of any heart attack: pressure, tightness, or pain in the center of the chest that may radiate to the left arm, jaw, neck, or back. You might also experience shortness of breath, nausea, lightheadedness, or a cold sweat. These symptoms can come on suddenly or build over minutes to hours.
What makes NSTEMI tricky is that it’s more likely than a STEMI to present in less obvious ways, particularly in women, older adults, and people with diabetes. In these groups, chest pain may be mild or absent altogether. Instead, the primary complaint might be unusual fatigue, indigestion, or unexplained shortness of breath. Because the symptoms can be vague, NSTEMI is sometimes dismissed as something less serious, which delays treatment and worsens outcomes.
How Doctors Confirm the Diagnosis
Two tools are central to diagnosing NSTEMI: an ECG and a blood test for a protein called troponin.
The ECG is done first and fast, often within minutes of arriving at a hospital. Doctors look for ST-segment depression or T-wave inversions. If ST elevation appears instead, the working diagnosis shifts to STEMI and treatment changes accordingly.
The blood test measures high-sensitivity cardiac troponin, a protein that heart muscle cells release when they’re injured. The diagnostic threshold is the 99th percentile of the normal range for the specific test being used, meaning any value above what 99% of healthy people would produce signals heart damage. These thresholds are sex-specific: women typically have lower normal values than men, so using a single cutoff for everyone would miss some heart attacks in women. A single elevated reading raises suspicion, but because troponin can rise from other causes (kidney disease, severe infections, heart failure), doctors usually draw blood at least twice, a few hours apart, to look for a rising or falling pattern that confirms a fresh heart attack.
Assessing How Serious It Is
Not every NSTEMI carries the same level of danger. Doctors use structured scoring systems to estimate risk and guide how urgently to intervene. The two most common are the GRACE score and the HEART score.
The GRACE score factors in age, heart rate, blood pressure, kidney function, and other clinical findings. A score of 108 or below indicates low risk, 109 to 139 is intermediate, and 140 or higher is high risk. The HEART score, which ranges from 0 to 10, uses a simpler set of inputs: the patient’s history, ECG findings, age, risk factors, and troponin level. Scores of 0 to 3 are low risk, 4 to 6 are moderate, and 7 to 10 are high risk.
These scores help determine whether you need an urgent procedure to open the blocked artery or whether a more conservative, medication-first approach is safe. High-risk patients are typically taken for an angiogram (a catheter-based imaging procedure to visualize the coronary arteries) within hours, while lower-risk patients may be monitored and scheduled for one within a day or two.
Short-Term and Long-Term Outlook
In the first 28 days after a heart attack, NSTEMI patients fare somewhat better than STEMI patients. One large study found 28-day mortality rates of 4.7% for NSTEMI compared to 6.7% for STEMI. After adjusting for age, sex, and severity, NSTEMI patients had roughly 42% lower odds of dying in that early window.
The longer-term picture is more sobering. At 10 years, death rates essentially converge: 22.8% for NSTEMI patients versus 19.6% for STEMI patients, a difference that was not statistically significant after accounting for other health factors. After surviving the first year, NSTEMI patients had an annual mortality rate of about 2.1%, slightly higher than the 1.6% for STEMI survivors. This pattern likely reflects the fact that NSTEMI patients tend to be older and have more underlying health conditions like diabetes, high blood pressure, and kidney disease, all of which continue to drive risk for years.
The takeaway: surviving the initial event is only part of the story. Long-term management of the conditions that led to the heart attack matters just as much.
Possible Complications
Serious complications during an NSTEMI are less common than during a STEMI, but they do occur. In one study of 480 NSTEMI patients, about 3.5% developed acute fluid buildup in the lungs (pulmonary edema), 0.8% went into cardiogenic shock (where the heart suddenly can’t pump enough blood), and 13.3% experienced some form of non-life-threatening rhythm disturbance.
Dangerous heart rhythm problems, including ventricular tachycardia, ventricular fibrillation, and complete heart block, occurred in about 2.3% of patients within the first 48 hours. Some of these episodes happened during or after the catheterization procedure itself. Three of the 480 patients in that study died from these rhythm disturbances. While these numbers are relatively small, they underscore why NSTEMI patients are monitored on continuous heart rhythm trackers during their hospital stay.
Recovery and Reducing Future Risk
After an NSTEMI, most people are started on a combination of medications to thin the blood, lower cholesterol, control blood pressure, and reduce the heart’s workload. If a stent was placed during catheterization, blood-thinning medications are especially important to keep the stent open.
Cardiac rehabilitation is one of the most effective tools for recovery. These supervised programs combine structured exercise with education on diet, stress management, and lifestyle changes. They’ve been shown to improve exercise capacity and quality of life while reducing mortality, future heart events, and unplanned hospital readmissions. More intensive programs that add dietary counseling, stress management techniques, and social support have been linked to even greater reductions in death from all causes.
Despite the evidence, many NSTEMI survivors never enroll in cardiac rehab. If you’ve had an NSTEMI and haven’t been referred, it’s worth asking about. The modifiable risk factors that caused the first event, smoking, inactivity, poorly controlled blood sugar, high cholesterol, don’t resolve on their own. The convergence of NSTEMI and STEMI mortality rates at 10 years is a clear signal that the underlying disease keeps progressing unless actively managed.